Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amphotericin B inhalation - Cystetic medicines

Next Previous
Drug Profile

Amphotericin B inhalation - Cystetic medicines

Alternative Names: ABCI - Cystetic Medicines; CM-001

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Illinois; University of Iowa Research Foundation
  • Developer cystetic Medicines; DevPro Biopharma
  • Class 1 ring heterocyclic compounds; Amides; Amines; Antifibrotics; Antifungals; Antiprotozoals; Carboxylic acids; Cycloparaffins; Macrolides; Small molecules
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cystic fibrosis

Most Recent Events

  • 28 Apr 2026 No recent reports of development identified for phase-I development in Cystic-fibrosis(In adolescents, In the elderly, In volunteers, In adults) in Australia (Inhalation, Powder)
  • 28 Apr 2026 No recent reports of development identified for phase-I development in Cystic-fibrosis(In adolescents, In the elderly, In volunteers, In adults) in New Zealand (Inhalation, Powder)
  • 18 Aug 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top